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Summary Insulin-like growth factor-binding proteins (IGFBPs) are important modulators of IGF action. In 50 children suffering from acute
lymphoblastic leukaemia (ALL), we studied the serum levels of IGFBP-1,-2 and-3. The mean standard deviation score (SDS) values were
estimated to be 0.7, 3.1 and -1.7 for the IGFBP-1,-2 and-3, respectively, compared with the normal range defined by a SDS from -2 to +2.
IGFBP-1 and-3 were normal, but for IGFBP-2 we found a significantly elevated serum level compared with control groups (P < 0.05).
However, during chemotherapy this increased serum IGFBP-2 normalized. In addition, we found a correlation between higher serum levels
and the detection rate of the IGFBP-2 transcript in corresponding cells. In patients with ALL, the detection rates of IGFBP-2 mRNA were
estimated to be 72% and 35% at the time of diagnosis and at day 33 of chemotherapy respectively; in the control groups (healthy children and
children at their initial presentation of diabetes mellitus), the values were 28% and 33% respectively. Based on the correlation between
IGFBP-2 serum levels and the corresponding gene expression as well as the normalization of IGFBP-2 levels during chemotherapy, we
concluded that the increased serum level mainly originated from the tumour clone itself. Furthermore, possible functional consequences of
elevated IGFBP-2 were outlined.
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Insulin-like growth factors (IGFs) are peptides with a number of
biological functions. They are involved in the regulation of
cellular proliferation, differentiation and metabolism (El-Brady et
al, 1989; Reeve and Kirby, 1992; Martin et al, 1993; Melino et al,
1993; Christofori et al, 1991). The effects of IGFs are mediated
by two different cell-surface receptors (Neely et al, 1991) at
autocrine, paracrine or endocrine levels (Li et al, 1993). The
majority of IGFs are secreted by the liver. Other cells, such as
immune or epithelial cells, only slightly contribute to the total
amount of these factors found in the circulation (Jones and
Clemmons, 1995). Only a small fraction of IGFs is biologically
active, because more than 90% of the IGFs are bound to proteins
called insulin-like growth factor-binding proteins (IGFBPs). As
yet, the family of these proteins consists of six well-known
(Rechler, 1993) and four new members (Kim et al, 1997).
An important functional implication of these IGFBPs is the
capturing of IGFs. By this process the binding rate of the IGFs
to their receptors is decreased, and subsequently the signal
transduction is affected (Czech, 1989; Clemmons et al, 1995).
Additionally, the binding may also contribute to a prolongation
of IGFs half-life by preventing their proteolytic degradation
(Clemmons, 1991; Rechler, 1993).
There are several reports providing evidence that tumour cells
frequently express IGFBP in vitro and in vivo. The IGFBP-1 was
detected in the serum of patients with ovarian carcinomas (Lino
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et al, 1986) and lung cancer (Reeve et al, 1992). Furthermore, the
IGFBP-2 was found in the supernatant of breast and prostate
cancer cells (Adamo et al, 1992; Reeve and Kirby, 1992) and
several other human tumour cell lines (Kanety et al, 1993),
suggesting IGFBP-2 gene expression by the tumour cells.
Recently, we investigated whether the elevated IGFBP-2 serum
levels found in ALL patients represents a marker for high risk of
relapse (Mohnike et al, 1997). In this study, 50 patients and 40
control probands were analysed with respect to their IGFBP-2
serum level as well as the corresponding gene expression by
reverse transciptase-polymerase chain reaction (RT-PCR).
The results presented here show that the increased serum level
of IGFBP-2 is generally accompanied by higher detection rates of
the corresponding transcript in the leukaemic cells. We concluded
that the tumour clone expresses IGFBP-2 and therefore plays an
active role in the regulation ofthe IGF concentration in the serum.
MATERIAL AND METHODS
Patient samples
Serum samples from bone marrow and/or peripheral blood were
obtained from 50 children (age 1.1-16.3 years, average 6.7 years)
with acute lymphoblastic leukaemia (ALL) at time of diagnosis
(B-precursor ALL, n = 7; B-ALL, n = 3; T-ALL, n = 10; c-ALL,
n = 28; not classified, n = 2) and from 14 patients at day 33 after
the onset of chemotherapy (pre-B-ALL, n = 2; c-ALL, n = 8;
T-ALL, n = 3; not classified, n = 1). All 14 patients were in full
haematological remission at day 33.
The control groups included 25 healthy children (age 3.0-17.1
years, average 9.3 years) as well as 15 children at their initial
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Figure 1 Serum levels of IGFBP-1, -2 and -3 from 50 children suffering from
ALL at time of diagnosis (a), healthy children (b) and diabetic children (c).
Values represent SDS calculated from absolute concentrations, which were
determined by radioimmunoassay as described in Material and methods.
Boxes indicate 10/90 percentile, median (left line) and mean (right line)
presentation of diabetes mellitus, before they received exogenous
insulin (age 2.9-15.1 years, average 8.5 years; HbAlc 8.5-
15.5%, average 11.3%; fructosamin 359-832 jtrmol 1-', average
596pitmol 1-1). Blood samples from healthy children had been
obtained during exclusion ofendocrinological diseases.
Mononuclear cells (MNC) were separated using ficoll gradient
centrifugation. At the time of diagnosis, the tumour clones gener-
ally represented 50-90% of MNC fraction. None of these patients
received any drugs before the first blood or bone marrow was
drawn.
Radioimmunoassay (RIA)
IGFBP-1, -2 and -3 were determined by radioimmunoassay as
described previously (Blum et al, 1990; Chard et al, 1994).
RNA isolation/cDNA synthesis
Total RNA was extracted using TRIzol reagent (Gibco) following
the manufacturer's protocol. The RNA was stored at -70°C until
use. Two micrograms of total RNA was transcribed into cDNA
by AMV reverse transcriptase (Reverse Transcription System,
Bioproducts) as recommended by the manufacturer.
Enzymatic amplification of the cDNA
A 2-tl aliquot ofthe cDNA reaction mixture was directly used for
enzymatic amplification, which was performed in 50 pl of reac-
tion buffer containing lx reaction buffer mixture (Prime Zyme,
Biometra), 1 unit of Taiq-polymerase (Biometra) and 0.2 pmol of
both IGFBP-2 primers (forward: 5'-Agg TTg CAg ACA ATg gCg
AT; reverse: 5'-gTA gAA gAg Atg ACA CTC gg) in a Hybaid
Gene Thermocycler (Biometra). Initial denaturation at 95°C for
3 min was followed by 35 cycles with denaturation at 95°C
for 1 min, annealing at 62°C for 1 min and elongation at 720C
for 2 min. The final elongation step was extended to 15 min.
One-fifth of each reaction mixture was loaded onto a 1.75%
agarose gel, separated by electrophoresis at 5 V cm-' in TAE
buffer and stained with ethidium bromide. The 3-actin PCR was
carried out using the same protocol and the following primers
(forward: 5'-TCA AAC ATg ATC Tgg gTC AT; reverse: 5'-CCC
Agg CAC CAg GgC gTg AT).
Restriction analysis
Ten microlitres of IGFBP-2 DNA obtained by RT-PCR were
digested with 10 units of PspMI (New England Biolabs) in the
recommended buffer system at 37°C for I h and analysed by
electrophoresis as described above.
Statistical analysis
Because of the log-normal distribution of investigated parameters,
values were transformed to their logarithms before constructing
the percentiles ofthe normal range and calculating standard devia-
tion scores (SDS) [SDS = (x-X)ISD; x = IGFBP measured value in
pg 1-, X = mean of IGFBP values in Rtg 1-', which are character-
istic ofthe age and sex ofthe single child; SD, standard deviation].
The significance of differences between groups was tested using
Student's t-test (P = 0.05).
RESULTS
Serum level of IGFBP-1, -2 and -3
IGFBP-1, -2 and -3 concentrations were analysed in the serum
from healthy children and diabetic children in comparison to ALL
patients. The values obtained from controls were found to be
between 12 and 177 tg 1-' (IGFBP-l), 57 and 841 ,ug 1' (IGFBP-
2) and 1331 and 4545 [.g 1- (IGFBP-3).
Table 1 Serum concentrations and SDS values from IGFBP-1, -2, -3 and IGF-I in healthy children and children at their initial presentation of diabetes
Healthy children Diabetic children
IGFBP-1 IGFBP-2 IGFBP-3 IGFBP-1 IGFBP-2 IGFBP-3
Concentration in (pg 1-') 12-53 54-468 1927-4414 15-177 90-706 1331-4813
SDS range -1.66-0.91 -4.51-1.11 -1.1-2.12 -0.46-3.49 -4.72-2.54 -3.6-1.09
SDS mean -0.7 -1.38 0.23 0.6 -0.8 -0.33
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Figure 2 The detection of IGFBP-2 mRNA by RT-PCR. Lanes 1-10 document PCR fragments obtained from patients or control probands as marked, lane M
represents the 100-bp marker (Gibco). The 496-bp DNA fragment is derived from the IGFBP-2 transcript, the 260-bp fragment represents the 3-actin mRNA
Because of the age-dependent variations in IGFBP concentra-
tions, the data are given in SDS. The normal range, represented by
SDS from -2 to +2, includes 80% of all values from both control
groups, the healthy probands as well as the diabetic children
(Figure 1). Healthy children and children at their initial presenta-
tion of diabetes demonstrated averages of SDS of -0.7 and 0.6
(IGFBP-1), -1.38 and -0.8 (IGFBP-2), and 0.23 and -0.33
(IGFBP-3) respectively (Table I and Figure 1). The differences
between both groups were found to be significant in IGFBP-1
(P < 0.05) but not in IGFBP-2 and -3. With respect to IGFBP-2
and -3, both groups were indistinguishable and therefore could be
considered as a unique control population.
On the contrary, IGFBP-2 serum levels were found to be signif-
icantly elevated at the time of diagnosis in patients with ALL
(Figure 1). The absolute concentrations of these factors were
determined to be in the range of 9-148 Peg 1-' for IGFBP-1.
247-4048 Pog 1' for IGFBP-2 or 433-4500,g 1-1 for IGFBP-3.
The averages of SDS of ALL patients were calculated to be 0.7 for
IGFBP- 1, 3.1 for IGFBP-2 or -1.7 for IGFBP-3 (Figure 1).
Significant differences (P < 0.05) were found for the IGFBP-2
values between the patients and the total control group as well as
both control groups separately.
During the therapy, IGFBP-2 serum levels normalized. The
absolute concentrations of IGFBP-2 determined at day 33 after
the onset of chemotherapy was in the range of 64-905 ag 1-1 or
represented an average SDS of-1.45. Only 2 of 14 samples (14%)
investigated revealed elevated serum levels at this time (Figure 4).
IGFBP-2 gene expression
To clarify whether the increased IGFBP-2 levels result at least partly
from the tumour cells, we studied IGFBP-2 gene expression from
leukaemic cells using RT-PCR. Using IGFBP-2-specific primers, we
detected a 496-bp DNA fragment, a size that was expected from the
known cDNA sequence (accession no. Xl16302) (Figure 2). To
exclude false-negative results, we also investigated the occurrence
of 1-actin mRNA. This transcript was found in 97% (101 of 104) of
all samples, indicating integrity ofthe RNA samples. The specificity
of PCR products was confirmed by restriction analysis using the
unique PpUM I site in the IGFBP-2 cDNA (Figure 3).
The IGFBP-2 transcript could be detected in 28C{ or 33% of
MNC fractions derived from healthy children or children with
diabetes respectively (Table 2). In children suffering from
leukaemia, the situation was markedly altered. Sixty per cent of all
patients displayed elevated IGFBP-2 serum levels at the time of
diagnosis. The IGFBP-2 mRNA was detectable in nearly 72% of
the corresponding MNC fractions of all patients (Table 2 and
Figure 4). Calculating separately the detection rate of patients
displaying increased or normal serum levels, the values were esti-
mated to be 86% or 45% respectively (Figure 4).
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Figure 3 Restriction analysis of IGFBP-2-derived PCR products. Five
independent PCR fragments obtained from ALL patients were cut using
PpUM as described. In accordance with the cDNA sequence (X16302), two
fragments with a length of 280 and 215 bp were detected. Lane 6 represents
the undigested 496-bp PCR product
The observed normalization of the IGFBP-2 serum during
chemotherapy was also accompanied by a decreased detection rate
of the transcript. IGFBP-2 mRNA was detected in 35% of these
samples only, a value similar to that determined for both control
groups (Table 2 and Figure 4).
DISCUSSION
It is known that malignant diseases lead to alterations in the IGF
signalling system (Bergmann et al, 1995; Figueroa et al, 1995;
Singh et al, 1996). Additionally, IGFs have been implicated in the
pathology of numerous tumours (Daughaday and Deuel, 1991).
Recently, we reported on changes in IGF-I and -II and some of
their binding proteins in children suffering from ALL and found the
first hints that the increased IGFBP-2 serum level may correlate with
the risk of relapse (Mohnike et al, 1996, 1997). As a result of the
observation that the elevated IGFBP-2 levels generally normalized
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during chemotherapy, we concluded that the tumour clone may be
directly or indirectly involved. In order to clarify the question
whether tumour clones express IGFBP-2, we studied the corre-
sponding gene expression of enriched tumour cells using RT-PCR
and analysed these data with respect to the IGFBP-2 serum levels.
At the time ofdiagnosis, IGFBP-2-mRNA was detected in 72%
of MNC samples isolated from ALL patients. In contrast, only
35% of the corresponding samples contained the IGFBP-2 tran-
script at day 33 of chemotherapy. This value is similar to that of
healthy or diabetic children, estimated to be 28% or 33% respec-
tively. The diabetic children were selected as a control group to
exclude the possibility that elevated IGFBP-2 serum level in ALL
patients simply originates from metabolic changes. Diabetic
patients suffer from a well-characterized disease in which only
insulin is lacking; they are comparable to ALL patients with
respect to their age and their catabolic situation, which is caused
by either insulin deficiency in diabetic children or tumour
cachexia in ALL children. The metabolism of both groups is
subjected to a caloric restriction. Both the diabetes control group
and the ALL patients at time ofdiagnosis showed decreased IGF-I
SDS values (Mohnike et al., 1996). As both the IGFBP-2 serum
levels and the detection rate ofthe transcript are nearly identical in
the healthy and diabetic children, metabolic alterations could not
account for elevations of serum IGFBP-2 found in children
suffering from ALL.
Furthermore, the results demonstrate that the majority of
samples with increased IGFBP-2 serum levels was accompanied
by the occurrence of IGFBP-2 mRNA in the corresponding MNC
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Figure 4 Correlation between the IGFBP-2 serum concentration and the occurrence of IGFBP-2 transcript in the corresponding MNC fraction. The dark area
represents the normal distribution of IGFBP-2 serum levels given in SDS from 50 ALL patients at time of diagnosis and 14 ALL patients during remission (A) as
well as from 15 diabetic children and 25 healthy probands (B). Each asterisk represents data obtained from one proband
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Table 2 IGFBP-2 serum levels and IGFBP-2 mRNA expression in children
suffering from ALL, healthy controls and children with diabetes
IGFBP-2 mRNA IGFBP-2 serum level
Not Elevated In normal
Detectable detectable (above range
2 SDS) (between -2
and +2 SDS)
ALL patients 72 28 60 40
at time of (36) (14) (30) (20)
diagnosis % (n)
ALL patients 35 65 14 86
in remission % (n) (5) (9) (2) (12)
Healthy 28 72 0 100
children % (n) (7) (18) (0) (25)
Children at 33 67 20 80
their initial (5) (10) (3) (12)
presentation
of diabetes % (n)
fraction. This implies that changes in IGFBP-2 serum level could
depend on the IGFBP-2 gene expression by the tumour clone. In
addition, this assumption is supported by the adjustment of serum
level and mRNA expression values observed after the destruction
of the tumour clone by chemotherapy.
Taking together the data from control samples as well as
patients during remission, it has to be noted that IGFBP-2 serum
levels were detectable in all samples, however the presence of
corresponding mRNA was shown in only 28-35%. Based on these
data, it is obvious that IGFBP-2 levels result from other non-
haematopoietic sources, e.g. liver. Therefore, serum IGFBP-2 has
to be considered as ajoint pool resulting from the gene expression
of different cells. This assumption of other IGFBP-2 sources is in
line with results of other authors demonstrating that haemato-
poietic cells contribute to the serum concentrations of the IGF-
regulatory peptides (Shimon and Shipilberg, 1995).
Taking into account results from all 104 measurements, elevated
serum levels but no mRNA were detected in five cases, four ALL
patients and one diabetic child, whereas the serum IGFBP-2 was
missing in six samples with positive mRNA values. At first glance,
these results may be considered to be wrong and not in line with
the hypothesis that the tumour clones represent the major cause of
the elevated IGFBP-2 levels. However, the proportion of these
data is less than 7% and they may reflect individual constitutions
ofthe probands as well as the quality of samples. It is well known
that an injury can lead to an increase in IGFBPs or IGFs caused
by secretion by the liver (Lang et al, 1996) and therefore to an
increase of serum IGFBP-2 without any cooperation of mono-
nuclear cells. Otherwise, the technical limitations of the RIA or
RT-PCR methods as well as differences during the transport, e.g.
RNA degradation, could be regarded as possible explanations.
However, despite the difficulties of explaining the exact cause of
these results discussed above, the clear association between the
occurrence of tumour cells and both parameters, the serum level
and mRNA data have been proven. Until now, we were not able to
definitely exclude the involvement of other tissues, such as the
liver or epithelial cells, whose IGFBP-2 expression may be
increased by the occurrence of tumour cells and therefore may
cause elevated serum levels. However, the strong association of
IGFBP-2 serum levels and the evidence of corresponding mRNA
of the enriched tumour cells points to the conclusion that the
elevated IGFBP-2 serum levels result from the gene expression of
the tumour cells.
This finding is in accordance with other reports describing
elevated IGFBP-2 levels in various malignant diseases, such as
prostate cancer (Kanety et al, 1993), Wilms' tumour (Zumkeller et
al, 1993) and lung cancer (Reeve and Payne, 1990). Whereas the
stimulation of cell proliferation by IGFs is well established
(Camacho-Hubner et al, 1991; Jones and Clemmons, 1995) the
functions of IGFBP-2 on tumour and normal cells are still
unknown. At the first sight, an increase in the IGF-binding
proteins should lead to an inhibition of cellular proliferation by
capturing IGFs. Therefore, the overexpression of IGFBP-2 seems
to be in direct conflict with the explanation ofthe higher prolifera-
tion rate of lymphoblastic cells. One possible explanation may be
that increased IGFBP-2 level serves as a storage pool of IGFs in
the pericellular microenvironment ofthese cells. Although there is,
as yet, no clear evidence, there are data supporting this idea.
Roghani and co-workers reported that IGFBP-2 binds IGF-II
rather than IGF-I (Roghani, 1991). Recently, it was shown that the
IGF-II/IGFBP-2 complex is partly bound to the extracellular
matrix (ECM) (Arai et al, 1996), where the IGF-II may be
liberated from this complex by limited proteolysis. Gockerman
and Clemmons (1995) described in porcine aortic smooth muscle
cells a constitutively secreted serine protease capable ofdegrading
IGFBP-2. Furthermore, they showed that the cleavage of IGFBP-2
into two fragments led to a strong reduction of the IGF-binding
capacity, resulting in liberation of the IGF-II and subsequently to
increased signal transduction (Binoux et al, 1994). Therefore, the
increased IGFBP-2 levels may provide a storage pool of ECM-
bound IGF/IGFBP-2 complex in the vicinity of tumour cells.
Based on this hypothetical model, the IGFBP-2 could be consid-
ered to be advantageous for the tumour cells. However, it needs
further experimental studies to confirm this hypothesis and reveal
the functional role of IGFBP-2 tumour cells.
Taken together, the data presented here clearly provide evidence
that the tumour clone itself is the major cause for the elevated
IGFBP-2 serum levels in patients suffering from leukaemia and
that the involvement of its gene expression may be the best expla-
nation. This finding may be helpful for further studies aimed on
the functional role of this binding protein and its potential as a
marker and/or target for clinical studies.
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